KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Interest Expenses (2023 - 2025)

Travere Therapeutics' Interest Expenses history spans 7 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 22.4% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $10.7 million, down 4.49%, while the annual FY2025 figure was $10.7 million, 4.46% down from the prior year.
  • Interest Expenses reached $2.2 million in Q4 2025 per TVTX's latest filing, down from $2.8 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.9 million in Q1 2025 to a low of $2.2 million in Q4 2025.
  • Average Interest Expenses over 3 years is $2.8 million, with a median of $2.8 million recorded in 2023.
  • The largest YoY upside for Interest Expenses was 3.57% in 2025 against a maximum downside of 22.4% in 2025.
  • A 3-year view of Interest Expenses shows it stood at $2.8 million in 2023, then increased by 0.04% to $2.8 million in 2024, then dropped by 22.4% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Interest Expenses are $2.2 million (Q4 2025), $2.8 million (Q3 2025), and $2.8 million (Q2 2025).